Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The OPTIMIZE Study
NCT06512194Phase 2Recruiting
- Start
- May 2025
- Primary completion
- May 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of psilocybin in major depressive disorder (MDD) (3 arms). Primary endpoints: Montgomery-Åsberg Depression Rating Scale at Week 8, PROMIS Ability to Participate in Social Roles and Activities - Short Form 8a at Week 8 and 1 more. Started May 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06512194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06512194.